Current Opinion in Oncology最新文献_第4页

Desmoplastic small round cell tumor. 结缔组织增生小圆细胞瘤。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-04-30 DOI: 10.1097/CCO.0000000000001239

Mehdi Brahmi, Clémence Romeo, Alexandra Meurgey, Margaux Dupont, Armelle Dufresne

{"title":"Desmoplastic small round cell tumor.","authors":"Mehdi Brahmi, Clémence Romeo, Alexandra Meurgey, Margaux Dupont, Armelle Dufresne","doi":"10.1097/CCO.0000000000001239","DOIUrl":"10.1097/CCO.0000000000001239","url":null,"abstract":"Purpose of review: Desmoplastic small round cell tumor (DSRCT) is an ultra-rare, fusion-driven sarcoma with a dismal prognosis despite multimodal therapy. Most patients present with advanced intra-abdominal and/or metastatic disease at diagnosis, and long-term survival remains uncommon. This review summarizes recent advances in the molecular and biological understanding of DSRCT. It highlights current diagnostic and therapeutic standards, and discusses emerging targeted and immunotherapeutic strategies with translational relevance.Recent findings: DSRCT is defined by the pathognomonic EWSR1::WT1 fusion, which acts as an aberrant transcription factor driving oncogenesis. Although there is no consensus standard of care, multimodal strategies combining dose-intense chemotherapy, complete cytoreductive surgery, and whole abdominopelvic radiotherapy remain the cornerstone of management when feasible. However, outcomes remain poor, particularly in patients with extra-peritoneal disease. Recent genomic studies have identified actionable vulnerabilities, including dysregulation of the angiogenic pathways, and IGF axis. In parallel, innovative immunotherapeutic approaches - particularly antibody-drug conjugates targeting HER2 and B7-H3 - have shown encouraging early signals of activity.Summary: Despite multimodal treatment, DSRCT remains a highly lethal malignancy. Advances in molecular characterization are reshaping the therapeutic landscape and supporting the development of targeted strategies, especially antibody-drug conjugates. Enrollment in prospective clinical trials and international collaborative efforts are essential to improve outcomes in this orphan disease.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"327-333"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intimal sarcoma, review and future perspectives. 内膜肉瘤，回顾和未来展望。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-05-20 DOI: 10.1097/CCO.0000000000001246

Santiago López Subires, Naroa Amondarain Amenabar, Claudia Valverde

{"title":"Intimal sarcoma, review and future perspectives.","authors":"Santiago López Subires, Naroa Amondarain Amenabar, Claudia Valverde","doi":"10.1097/CCO.0000000000001246","DOIUrl":"10.1097/CCO.0000000000001246","url":null,"abstract":"Purpose of review: Intimal sarcoma is an exceptionally rare and aggressive vascular malignancy that remains frequently misdiagnosed. This review synthesizes recent advances in epidemiology, diagnosis, molecular characterization and treatment, highlighting why updated guidance is urgently needed.Recent findings: Current literature emphasizes persistent diagnostic delays due to nonspecific clinical and radiological features. Molecular studies consistently show recurrent amplification of MDM2, PDGFRA and CDK4 as key oncogenic drivers. Surgical resection remains the only potentially curative option, although complete removal is often challenging. Retrospective data suggest that multimodal therapy, particularly anthracycline-based chemotherapy, may improve outcomes in selected patients. Targeted therapies and immunotherapy have shown limited but emerging activity in moleculary defined subgroups.Summary: Despite incremental progress, prognosis remains poor, underscoring the need for earlier recognition, molecularly guided treatment strategies and clinical trial participation. Management in specialized multidisciplinary centers is essential to optimized care and advance research in this ultra-rare sarcoma.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"310-318"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148027968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial. 社论。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-04 DOI: 10.1097/CCO.0000000000001244

Florian Scotté, Didier Mayeur

引用次数: 0

Cancer survivors living with chronic pain: patient and healthcare professional perspectives and current recommendations. 患有慢性疼痛的癌症幸存者：患者和医疗保健专业观点和当前建议。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-05-14 DOI: 10.1097/CCO.0000000000001240

Julie Armoogum, Colleen Cuthbert

{"title":"Cancer survivors living with chronic pain: patient and healthcare professional perspectives and current recommendations.","authors":"Julie Armoogum, Colleen Cuthbert","doi":"10.1097/CCO.0000000000001240","DOIUrl":"10.1097/CCO.0000000000001240","url":null,"abstract":"Purpose of review: Chronic pain affects approximately 40% of cancer survivors and remains an under recognized and complex condition. This review is timely given the growing population of cancer survivors and the persistent gaps in evidence-based guidance for managing chronic post-cancer treatment pain. It synthesizes recent research (primarily since 2024) to inform clinical practice and future guideline development.Recent findings: Three key themes emerged: inadequate pain assessment and communication, compounded by negative clinical and societal attitudes; opioid stigma and uncertainty regarding long-term benefits, creating barriers for both patients and clinicians; and the role of self-management strategies, including physical activity, psychological support, and multimodal approaches.Summary: Findings underscore the need for updated clinical guidelines, enhanced education for healthcare professionals, and patient-centred strategies that integrate pharmacologic and nonpharmacologic options. Future research should prioritize robust intervention development and evaluation to improve quality of life and reduce the burden of chronic pain in cancer survivorship.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"269-274"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148027911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development. 70岁的5-氟尿嘧啶：仍然有吸引力，但几乎不被理解。这是一个药物开发的警示故事。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-04 DOI: 10.1097/CCO.0000000000001247

Alain Hendlisz

引用次数: 0

Survivorship: new achievements and new challenges. 生存：新的成就和新的挑战。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-07-01 Epub Date: 2026-06-04 DOI: 10.1097/CCO.0000000000001253

Jean A Klastersky

引用次数: 0

Circulating tumor DNA in human papilloma virus negative head and neck squamous cell carcinoma. 人乳头瘤病毒阴性头颈部鳞状细胞癌循环肿瘤DNA。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-05-01 Epub Date: 2026-01-22 DOI: 10.1097/CCO.0000000000001210

Rachel Galot, Jean-Pascal Machiels

{"title":"Circulating tumor DNA in human papilloma virus negative head and neck squamous cell carcinoma.","authors":"Rachel Galot, Jean-Pascal Machiels","doi":"10.1097/CCO.0000000000001210","DOIUrl":"10.1097/CCO.0000000000001210","url":null,"abstract":"Purpose of review: Human papilloma virus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) remains a challenging disease with poor prognosis. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker to improve risk stratification, detect minimal residual disease (MRD), and guide treatment adaptation. This review synthesizes recent advances in ctDNA technologies and their clinical relevance for HPV-negative HNSCC.Recent findings: Technical progress has significantly improved ctDNA detection, with tumor-informed assays achieving limits of detection near 0.01% VAF and tumor-agnostic strategies offering broader applicability. Across studies, ctDNA is detectable in approximately 80% of HNSCC patients, though performance varies with tumor burden and assay sensitivity. In the postcurative setting, ctDNA positivity consistently identifies patients at high risk for relapse, often months before radiologic detection. Early data suggest that ctDNA kinetics may reflect treatment response. In R/M HNSCC, baseline ctDNA detection exceeds 90%, and on-treatment ctDNA decrease correlates with improved survival. Interventional studies, including ctDNA-guided adjuvant (de-)escalation approaches are ongoing.Summary: ctDNA represents a potential biomarker for MRD detection and response monitoring in HPV-negative HNSCC. Despite encouraging pilot studies, clinical utility remains to be proven. Well powered, prospective, ctDNA-driven trials are essential to validate how ctDNA can guide therapeutic intensification, de-escalation, and personalized treatment strategies in HNSCC.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"155-160"},"PeriodicalIF":2.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor microenvironment-driven immune evasion and therapeutic strategies in head and neck squamous cell carcinoma. 头颈部鳞状细胞癌肿瘤微环境驱动的免疫逃避及治疗策略。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-05-01 Epub Date: 2026-01-22 DOI: 10.1097/CCO.0000000000001212

Ingeborg Tinhofer, Anne-Sophie Fisch

{"title":"Tumor microenvironment-driven immune evasion and therapeutic strategies in head and neck squamous cell carcinoma.","authors":"Ingeborg Tinhofer, Anne-Sophie Fisch","doi":"10.1097/CCO.0000000000001212","DOIUrl":"10.1097/CCO.0000000000001212","url":null,"abstract":"Purpose of review: Head and neck squamous cell carcinoma (HNSCC) develops within a complex tumor microenvironment (TME) that fosters immune evasion and limits the efficacy of immune checkpoint inhibitors (ICIs). Despite advances, durable responses to ICIs remain limited, partly because of stromal barriers, myeloid cell recruitment, and metabolic constraints within the TME.Recent findings: Multiplex IHC/mIF, single-cell and spatial omics, and computational TME profiling reveal recurrent resistance programs, including CAF-driven immune exclusion, chemokine-dependent and hypoxia-dependent recruitment of myeloid cells and regulatory T cells, and nutrient and oxygen competition that constrain effector T cells. These insights underpin emerging TME-targeted combinations with PD-(L)1 blockade, such as VEGFR/multikinase and TGF-β/CAF-directed agents, myeloid and chemokine modulators, and metabolic interventions now being tested in solid tumors and increasingly in HNSCC.Summary: The HNSCC TME is both a central barrier and an attractive therapeutic target. Embedding high-resolution TME profiling into clinical trials will be crucial to select TME-matched combinations and identify patient subsets most likely to derive durable benefit from immunotherapy.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"176-186"},"PeriodicalIF":2.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Upper tract urothelial carcinoma associated with Lynch syndrome. 与Lynch综合征相关的上尿路上皮癌。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-05-01 Epub Date: 2026-04-02 DOI: 10.1097/CCO.0000000000001238

R Chelluri, S Kovell, F Montanaro, E Chandran, A Rouf Banday, Sandeep Gurram, Andrea B Apolo

引用次数: 0

Recent highlights and breakthroughs in immunotherapy for head and neck cancers. 头颈癌免疫治疗的最新亮点和突破。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2026-05-01 Epub Date: 2026-03-05 DOI: 10.1097/CCO.0000000000001211

Joanna A Vuille, Petr Szturz

{"title":"Recent highlights and breakthroughs in immunotherapy for head and neck cancers.","authors":"Joanna A Vuille, Petr Szturz","doi":"10.1097/CCO.0000000000001211","DOIUrl":"10.1097/CCO.0000000000001211","url":null,"abstract":"Purpose of review: This review highlights recent advances in immunotherapy for head and neck oncology, focusing on pivotal studies, both early-stage and late-stage, published or presented in 2025.Recent findings: Noteworthy results were reported with immune checkpoint inhibitors in mucosal squamous cell carcinoma of the head and neck (SCCHN) (KEYNOTE-689 and NIVOPOSTOP trials evaluating pembrolizumab and nivolumab, respectively, in the perioperative setting); in nasopharyngeal carcinoma (DIPPER and DIAMOND trials evaluating camrelizumab and toripalimab, respectively, in the curative setting with radiotherapy, and tagitanlimab in recurrent and/or metastatic disease); in cutaneous squamous cell carcinoma of the head and neck region (C-POST trial in the adjuvant setting and the combination of avelumab with cetuximab in the palliative setting); and in BRAF V600E-mutated anaplastic thyroid carcinoma (pembrolizumab with dabrafenib and trametinib). Passive immunotherapy targeting tumor-associated antigens also showed encouraging activity in R/M-SCCHN (petosemtamab, ficerafusp-alfa, amivantamab, enfortumab vedotin) and in heavily pretreated R/M nasopharyngeal carcinoma (antibody-drug conjugates becotatug vedotin and izalontamab brengitecan [iza-bren]).Summary: Recent advances highlight a rapid surge in positive immunotherapy trials across different head and neck cancer entities, with clinical benefit observed both when immune checkpoint inhibitors are moved earlier in the disease course and when they are combined with agents targeting resistance mechanisms or enabling more precise drug delivery to tumors.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"201-211"},"PeriodicalIF":2.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13052391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0